Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

90.56 USD UNCHANGED
Streaming Delayed Price Updated: 7:01 AM EST, Jan 19, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Incyte Corp

< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
From ACCESSWIRE
Incyte and MorphoSys Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
From PR Newswire
Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804
Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804 
From Business Wire News Releases
Incyte Announces Results of Phase 3 RUXCOVID Study of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm
Incyte Announces Results of Phase 3 RUXCOVID Study of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm 
From Business Wire News Releases
Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that The New England Journal of Medicine has published peer-reviewed results from the Adaptive COVID-19 Treatment Trial... 
From PR Newswire
Incyte to Present at Upcoming Investor Conference
Incyte (Nasdaq:INCY) announced today that it will present at the 39th Annual J. P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021 at 7:30 a.m. EST. 
From Business Wire News Releases
Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020
From ACCESSWIRE
Incyte Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Incyte Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with r/r B-Cell Non-Hodgkin Lymphomas 
From Business Wire News Releases
Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020
Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020 
From Business Wire News Releases
Incyte Announces First Data from REACH3 Trial Showing Ruxolitinib (Jakafi®) Significantly Improved Outcomes in Patients with Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease
First Data from REACH3 Show Ruxolitinib (Jakafi) Significantly Improved Outcomes in Patients with Steroid-Refractory or Steroid-Dependent cGVHD 
From Business Wire News Releases
New Pharma Trials Making Big Gains in Fight Against Triple-Negative Breast Cancer (TNBC)
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
New Pharma Trials Making Big Gains in Fight Against Triple-Negative Breast Cancer (TNBC)
FN Media Group Presents USA News Group News Commentary 
From PR Newswire
Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19
- ACTT-2 data serve as basis for EUA, the second COVID-19 authorization for a Lilly treatment 
From PR Newswire
Incyte to Present at Upcoming Investor Conference
Incyte (Nasdaq:INCY) announced today that it will present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference on Tuesday, December 1, 2020 at 10:30 a.m. EST. 
From Business Wire News Releases
Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab
Xencor (NASDAQ: XNCR), MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and Incyte (NASDAQ: INCY) today announced a clinical collaboration to investigate the combination of... 
From Business Wire News Releases
Data from Incyte’s Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer 2020 Annual Meeting
Incyte (Nasdaq:INCY) today announced that abstracts highlighting data from its oncology portfolio will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, held virtually from... 
From Business Wire News Releases
Incyte Reports 2020 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
Incyte Reports 2020 Third Quarter Financial Results and Provides Updates on Key Clinical Programs 
From Business Wire News Releases
More than 40 Abstracts from Incyte’s Oncology Portfolio Accepted for Presentation at the 62nd Annual ASH Virtual Meeting
More than 40 Abstracts from Incyte’s Oncology Portfolio Accepted for Presentation at the 62nd Annual ASH Virtual Meeting 
From Business Wire News Releases
ACR 2020: Lilly and Incyte Highlight Positive Data for Olumiant® in Rheumatoid Arthritis
Latest long-term safety and efficacy data on Olumiant reinforce the medicine's potential to help people living with rheumatoid arthritis (RA) 
From PR Newswire
EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis
- Latest baricitinib data highlight long-term efficacy and safety results from BREEZE-AD3 trial 
From PR Newswire
Incyte Ranked Second Among Science Magazine’s 2020 Top Biopharma Employers
Incyte Ranked Second Among Science Magazine’s 2020 Top Biopharma Employers 
From Business Wire News Releases
Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata
- Data support baricitinib's ongoing Phase 3 program and potential to be the first approved medicine for people living with alopecia areata (AA) 
From PR Newswire
Pooled Results from Incyte’s TRuE-AD1 and TRuE-AD2 Atopic Dermatitis Studies of Ruxolitinib Cream Show Clinically Meaningful Improvements in Patient-Reported Quality of Life Assessments
Results from Incyte’s Atopic Dermatitis Studies of Ruxolitinib Cream Show Clinically Meaningful Improvements in Patient-Reported QoL Assessments. 
From Business Wire News Releases
Clinical Trials Delivering New Optimism in Fight Against Triple-Negative Breast Cancer
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Clinical Trials Delivering New Optimism in Fight Against Triple-Negative Breast Cancer
FN Media Group Presents USA News Group News Commentary 
From PR Newswire
Incyte to Report Third Quarter Financial Results
Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Thursday, November 5, 2020. 
From Business Wire News Releases
Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen
Further results from NIAID-sponsored ACTT-2 Trial Presented Today 
From PR Newswire
Nimble Announces Strategic Research Collaboration with Incyte to Discover Novel Peptide-Based Therapeutics
Nimble Therapeutics Inc. today announced the company has entered into a strategic collaboration with Incyte (NASDAQ: INCY) to discover first-in-class peptide therapies across various disease areas. 
From Business Wire News Releases
CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
Positive Opinion is the First Regulatory Action for Baricitinib as an Atopic Dermatitis Medicine 
From PR Newswire
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal
Encouraging Results from Phase 2 Trial of Retifanlimab in Patients with Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.